7,783 Shares in Becton, Dickinson and Company $BDX Purchased by Global Retirement Partners LLC

Key Points

• Global Retirement Partners LLC initiated a position in Becton, Dickinson and Company by purchasing 7,783 shares valued at approximately $1.18 million. Institutional investors and hedge funds collectively own 86.97% of BDX.
• BDX reported quarterly EPS of $3.23, exceeding estimates of $3.14, while revenue rose 5.4% year over year to $4.98 billion. The company reaffirmed fiscal 2026 EPS guidance of $12.62–$12.72.
• The company declared a quarterly dividend of $1.05 per share, equal to a 2.3% annualized yield. Analysts maintain a consensus “Hold” rating with an average price target of $185.67, while insiders have sold 11,779 shares worth nearly $2 million over the past three months.

Global Retirement Partners LLC bought a new position in shares of Becton, Dickinson and Company (NYSE:BDX - Free Report) during the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor bought 7,783 shares of the medical instruments supplier's stock, valued at approximately $1,178,000.

A number of other institutional investors and hedge funds have also made changes to their positions in BDX. Imprint Wealth LLC acquired a new stake in Becton, Dickinson and Company during the third quarter worth approximately $25,000. SHP Wealth Management acquired a new stake in Becton, Dickinson and Company in the fourth quarter valued at $26,000. Prosperity Bancshares Inc purchased a new stake in shares of Becton, Dickinson and Company during the 4th quarter worth approximately $29,000. WPG Advisers LLC increased its holdings in Becton, Dickinson and Company by 64.2% during the 4th quarter. WPG Advisers LLC now owns 156 shares of the medical instruments supplier's stock valued at $30,000 after acquiring an additional 61 shares in the last quarter. Finally, Kohmann Bosshard Financial Services LLC purchased a new position in Becton, Dickinson and Company during the fourth quarter worth $32,000. 86.97% of the stock is owned by institutional investors and hedge funds.

Becton, Dickinson and Company Trading Down 0.6%

Becton, Dickinson and Company stock opened at $182.39 on Tuesday. The company has a quick ratio of 0.51, a current ratio of 0.87 and a debt-to-equity ratio of 0.55. The business has a 50 day moving average price of $158.48 and a two-hundred day moving average price of $161.26. Becton, Dickinson and Company has a 12 month low of $127.59 and a 12 month high of $187.35. The stock has a market cap of $50.26 billion, a price-to-earnings ratio of 54.94, a price-to-earnings-growth ratio of 12.93 and a beta of 0.19.

Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last issued its earnings results on Thursday, August 6th. The medical instruments supplier reported $3.23 EPS for the quarter, beating the consensus estimate of $3.14 by $0.09. The company had revenue of $4.98 billion for the quarter, compared to the consensus estimate of $4.89 billion. Becton, Dickinson and Company had a net margin of 4.52% and a return on equity of 14.79%. The firm's revenue for the quarter was up 5.4% compared to the same quarter last year. During the same quarter in the previous year, the company earned $3.68 EPS. Becton, Dickinson and Company has set its FY 2026 guidance at 12.620-12.720 EPS. As a group, equities analysts forecast that Becton, Dickinson and Company will post 12.67 EPS for the current year.

Becton, Dickinson and Company Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Wednesday, September 30th. Stockholders of record on Wednesday, September 9th will be given a dividend of $1.05 per share. This represents a $4.20 dividend on an annualized basis and a dividend yield of 2.3%. The ex-dividend date of this dividend is Wednesday, September 9th. Becton, Dickinson and Company's dividend payout ratio (DPR) is currently 126.51%.

Insiders Place Their Bets

In related news, EVP Michael David Garrison sold 1,100 shares of the stock in a transaction that occurred on Wednesday, June 24th. The stock was sold at an average price of $145.66, for a total transaction of $160,226.00. Following the completion of the transaction, the executive vice president directly owned 13,172 shares of the company's stock, valued at approximately $1,918,633.52. This represents a 7.71% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Roland Goette sold 2,438 shares of the business's stock in a transaction on Tuesday, August 11th. The stock was sold at an average price of $180.84, for a total transaction of $440,887.92. Following the transaction, the executive vice president owned 14,856 shares in the company, valued at approximately $2,686,559.04. The trade was a 14.10% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders have sold 11,779 shares of company stock worth $1,974,669. Company insiders own 0.40% of the company's stock.

Analysts Set New Price Targets

A number of research firms have recently commented on BDX. TD Cowen upped their price objective on shares of Becton, Dickinson and Company from $163.00 to $182.00 and gave the company a "hold" rating in a research note on Wednesday, August 5th. Stifel Nicolaus set a $195.00 price target on shares of Becton, Dickinson and Company in a research report on Friday, August 7th. Piper Sandler increased their target price on Becton, Dickinson and Company from $161.00 to $175.00 and gave the stock a "neutral" rating in a research report on Friday, August 7th. Bank of America reduced their price target on shares of Becton, Dickinson and Company from $177.00 to $170.00 in a research note on Friday, June 12th. Finally, Weiss Ratings restated a "sell (d+)" rating on shares of Becton, Dickinson and Company in a report on Friday, August 7th. Eight analysts have rated the stock with a Buy rating, eight have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of "Hold" and an average price target of $185.67.

About Becton, Dickinson and Company

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD's products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company's operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD's product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source